United Therapeutics (UTHR) Enterprise Value (2009 - 2026)

United Therapeutics (UTHR) has 18 years of Enterprise Value data on file, last reported at -$2.2 billion in Q1 2026.

• For the quarter ending Q1 2026, Enterprise Value rose 35.15% year-over-year to -$2.2 billion; the trailing twelve-month figure through Mar 2026 stood at -$2.2 billion (up 35.15% YoY), and the FY2025 full-year result was -$2.9 billion, up 10.61% from the prior year.
• Enterprise Value improved to -$2.2 billion in Q1 2026, from -$2.9 billion in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$2.2 billion in Q1 2026 to a low of -$3.3 billion in Q3 2024.
• A 5-year average of -$2.8 billion and a median of -$2.9 billion in 2023 frame the typical range for Enterprise Value.
• Across the five-year window, Enterprise Value tumbled 47.03% in 2022 and jumped 35.15% in 2026, its largest moves.
• Tracing UTHR's Enterprise Value over 5 years: stood at -$2.8 billion in 2022, then slipped by 5.47% to -$3.0 billion in 2023, then dropped by 9.11% to -$3.3 billion in 2024, then rose by 10.61% to -$2.9 billion in 2025, then climbed by 26.25% to -$2.2 billion in 2026.
• Business Quant data shows UTHR's Enterprise Value at -$2.2 billion in Q1 2026, -$2.9 billion in Q4 2025, and -$2.8 billion in Q3 2025.